Pear Therapeutics (PEAR) reported Q4 EPS of $0.13, $0.54 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.32 million versus the consensus estimate of $1.47 million.
GUIDANCE:
Pear Therapeutics sees FY2022 revenue of $22 million.
For earnings history and earnings-related data on Pear Therapeutics (PEAR) click here.